Prognostically, specific autoantibody profiles signal heightened risk for organ-threatening complications, including anti-MDA5 antibodies for rapidly progressive interstitial lung disease [40,41,42,43,44], anti-RNA polymerase III antibodies for scleroderma renal crisis and malignancy surveillance [49,50,51,52,53], and anti-Ro52 antibodies for increased lymphoma susceptibility [54,55,56,57,58,59,60,61,62,63,64]. This evidence concerns the gene TRIM21 and interstitial lung disease.